Defective Mycobacterium tuberculosis antigen presentation by monocytes from tuberculosis patients

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 9, 2013, Pages 1229-1234

  Tung, Y C ^a,b   Ou, T T ^c   Tsai, W C ^c,d  

^a Department of Public Health and Environmental Medicine ^*  (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c Internal Medicine   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Monocyte; Tuberculosis; Vitamin D

Indexed keywords

CALCIFEDIOL; MYCOBACTERIUM ANTIGEN; VITAMIN D;

ADULT; ANTIGEN PRESENTATION; ARTICLE; BACTERIUM IDENTIFICATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE; TUBERCULOSIS;

EID: 84883048296     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0984     Document Type: Article

References (41)

1. World Health Organization. Global tuberculosis report, 2012. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
2. Kim J. Influence of vitamin D receptor polymorphism on tuberculosis among South Korean. Am J Respiratory Crit Care Med 2011; 183: A3346.
3. Jereb J, Etkind S C, Joglar O T, Moore M, Taylor Z. Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999. Int J Tuberc Lung Dis 2003; 7: S384-S390.
4. Andrews J R, Noubary F, Walensky R P, et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2012; 54: 784-791.
5. Mokrousov I, Wu X R, Vyazovaya A, et al. Polymorphism of 3′UTR region of TNFR2 coding gene and its role in clinical tuberculosis in Han Chinese pediatric population. Infect Genet Evol 2011; 11: 1312-1318.
6. Zhang Y, Zhang J, Zeng L, et al. The-2518a/g polymorphism in the mcp-1 gene and tuberculosis risk: a meta-analysis. PloS ONE 2012; 7: e38918.
7. Younga D, Verreck F A. Creativity in tuberculosis research and discovery. Tuberculosis 2012; 92 (Suppl 1): S14-S16.
8. Walzl G, Ronacher K, Hanekom W, et al. Immunological biomarkers of tuberculosis. Nature reviews. Immunology 2011; 11: 343-354.
9. Armstrong J A, Hart P D. Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes. J Exp Med 1971; 134: 713-740.
10. Goren M B, Vatter A E, Fiscus J. Polyanionic agents as inhibitors of phagosome-lysosome fusion in cultured macrophages: evolution of an alternative interpretation. J Leukoc Biol 1987; 41: 111-121.
11. Myrvik Q N, Leake E S, Wright M J. Disruption of phagosomal membranes of normal alveolar macrophages by the h37rv strain of Mycobacterium tuberculosis. A correlate of virulence. Am Rev Respir Dis 1984; 129: 322-328.
12. Chan J, Xing Y, Magliozzo R S, et al. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J Exp Med 1992; 175: 1111-1122.
13. Flesch I E, Kaufmann S H. Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Infect Immun 1991; 59: 3213-3218.
14. Nathan C F, Hibbs J B Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Current Opin Immunol 1991; 3: 65-70.
15. Pfeifer J D, Wick M J, Roberts R L, et al. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 1993; 361: 359-362.
16. Maffei A, Papadopoulos K, Harris P E. MHC class I antigen processing pathways. Human Immunol 1997; 54: 91-103.
17. Androlewicz M J, Cresswell P. How selective is the transporter associated with antigen processing? Immunity 1996; 5: 1-5.
18. Flynn J L, Goldstein M M, Triebold K J, et al. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 1992; 89: 12013-12017.
19. Kobashi Y, Abe M, Mouri K, et al. Usefulness of tuberculin skin test and three interferon-gamma release assays for the differential diagnosis of pulmonary tuberculosis. Intern Med 2012; 51: 1199-1205.
20. Cooper A M. Cell-mediated immune responses in tuberculosis. Ann Rev Immunol 2009; 27: 393-422.
21. Ernst J D. The immunological life cycle of tuberculosis. Nature reviews. Immunology 2012; 12: 581-591.
22. Grad R. Cod and the consumptive: a brief history of cod-liver oil in the treatment of pulmonary tuberculosis. Pharm Hist 2004; 46: 106-120.
23. Deluca H F. Historical overview of vitamin D. In: Feldman D, Pike J W, Adams J S, eds. Vitamin D. 3rd ed. London, UK: E lsevier, 2011.
24. Ralph A R, Lucas R M, Norval M. Vitamin D and solar ultraviolet radiation in the risk and treatment of tuberculosis. Lancet Infect Dis 2013; 13: 77-88.
25. Fares A. Seasonality of tuberculosis. J Glob Infect Dis 2011; 3: 46-55.
26. Abe E, Miyaura C, Sakagami H, et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1981; 78: 4990-4994.
27. Manolagas S C, Yu X P, Girasole G, et al. Vitamin D and the hematolymphopoietic tissue: a 1994 update. Semin Nephrol 1994; 14: 129-143.
28. Yang H F, Zhang Z H, Chang Z Q, et al. Vitamin D deficiency affects the immunity against Mycobacterium tuberculosis infection in mice. Clin Exp Med 2012; Aug 10. [Epub ahead of print]
29. Babb C, van der Merwe L, Beyers N, et al. Vitamin D receptor gene polymorphisms and sputum conversion time in pulmonary tuberculosis patients. Tuberculosis 2007; 87: 295-302.
30. Martineau A R, Timms P M, Bothamley G H, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377: 242-250.
31. Chien C H, Lai J N, Liao C F, et al. Mifepristone acts as progesterone antagonist of non-genomic responses but inhibits phytohemagglutinin-induced proliferation in human T-cells. Hum Reprod 2009; 24: 1968-1975.
32. Cabioglu N, Bilgic S, Deniz G, et al. Decreased cytokine expression in peripheral blood leukocytes of patients with severe sepsis. Arch Surg 2002; 137: 1037-1043; discussion 1043.
33. Cohen M S, Mesler D E, Snipes R G, et al. 1,25-dihydroxyvitamin D3 activates secretion of hydrogen peroxide by human monocytes. J Immunol 1986; 136: 1049-1053.
34. Sly L M, Lopez M, Nauseef W M, et al. 1alpha,25-dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase. J Biol Chem 2001; 276: 35482-35493.
35. James S Y, Williams M A, Kelsey S M, et al. The role of vitamin D derivatives and retinoids in the differentiation of human leukaemia cells. Biochem Pharmacol 1997; 54: 625-634.
36. Ostrem V K, Lau W F, Lee S H, et al. Induction of monocytic differentiation of HL-60 cells by 1,25-dihydroxyvitamin D analogs. J Biol Chem 1987; 262: 14164-14171.
37. Wejse C, Gomes V F, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respiratory Crit Care Med 2009; 179: 843-850.
38. Coussens A K, Wilkinson R J, Hanifa Y, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci USA 2012; 109: 15449-15454.
39. Salahuddin N, Ali F, Hasan Z, et al. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT study [Supplementary Cholecalciferol in Recovery from Tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis. BMC Infect Dis 2013; 13: 22.
40. Martineau A R, Wilkinson R J, Wilkinson K A, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respiratory Crit Care Med 2007; 176: 208-213.
41. Ueta C, Tsuyuguchi I, Kawasumi H, et al. Increase of gamma/delta T-cells in hospital workers who are in close contact with tuberculosis patients. Infect Immunity 1994; 62: 5434-5441.